Literature DB >> 10498888

Mouse models of prostate cancer.

P Sharma1, N Schreiber-Agus.   

Abstract

The pathogenetic basis of prostate cancer remains highly elusive; its clarification could be facilitated greatly by laboratory and clinical models of the disease. Although the genetically manipulated mouse has been invaluable for the modeling of other human cancer types, it has fared less well with respect to prostate cancer. Nevertheless, several highly valuable transgenic models exist and are highlighted in this review. Emerging reagents and strategies may allow us to use the mouse more effectively to define the molecular, cellular and physiological events that lead to prostate cancer initiation and progression.

Entities:  

Mesh:

Year:  1999        PMID: 10498888     DOI: 10.1038/sj.onc.1203037

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  2,3,7,8-Tetrachlorodibenzo-p-dioxin has both pro-carcinogenic and anti-carcinogenic effects on neuroendocrine prostate carcinoma formation in TRAMP mice.

Authors:  Robert W Moore; Wayne A Fritz; Andrew J Schneider; Tien-Min Lin; Amanda M Branam; Stephen Safe; Richard E Peterson
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-03       Impact factor: 4.219

2.  A C-14 labeled Py-Im polyamide localizes to a subcutaneous prostate cancer tumor.

Authors:  Jevgenij A Raskatov; James W Puckett; Peter B Dervan
Journal:  Bioorg Med Chem       Date:  2014-04-16       Impact factor: 3.641

3.  RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Authors:  Elizabeth Ahern; Heidi Harjunpää; Jake S O'Donnell; Stacey Allen; William C Dougall; Michele W L Teng; Mark J Smyth
Journal:  Oncoimmunology       Date:  2018-02-14       Impact factor: 8.110

4.  ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.

Authors:  Liem T Nguyen; Maria S Tretiakova; Mark R Silvis; Jared Lucas; Olga Klezovitch; Ilsa Coleman; Hamid Bolouri; Vassily I Kutyavin; Colm Morrissey; Lawrence D True; Peter S Nelson; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

5.  Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.

Authors:  M Stanbrough; I Leav; P W Kwan; G J Bubley; S P Balk
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

6.  Prostatic intraepithelial neoplasia in genetically engineered mice.

Authors:  Jae-Hak Park; Judy E Walls; Jose J Galvez; Minjung Kim; Cory Abate-Shen; Michael M Shen; Robert D Cardiff
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

Authors:  Ye Zhou; Maya Otto-Duessel; Miaoling He; Susan Markel; Tim Synold; Jeremy O Jones
Journal:  J Mol Endocrinol       Date:  2013-06-29       Impact factor: 5.098

8.  Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model.

Authors:  Sue Ellen Touma; Sven Perner; Mark A Rubin; David M Nanus; Lorraine J Gudas
Journal:  Biochem Pharmacol       Date:  2009-06-21       Impact factor: 5.858

Review 9.  Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?

Authors:  Nancy E Moran; Jennifer M Thomas-Ahner; Lei Wan; Krystle E Zuniga; John W Erdman; Steven K Clinton
Journal:  J Nutr       Date:  2022-06-09       Impact factor: 4.687

Review 10.  Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease.

Authors:  Natalie Sampson; Peter Berger; Christoph Zenzmaier
Journal:  Oxid Med Cell Longev       Date:  2012-10-22       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.